Prize4Life establishes ALS database
Prize4Life created the database with the Massachusetts General Hospital, with financing from the ALS Therapy Alliance, a US NPO.
Prize4Life said, "PRO-ACT is a powerful tool that merges data from existing publicly and privately conducted ALS clinical trials and makes these data widely available for research, creating an invaluable resource for accelerating discovery in the field of ALS."
"With the creation of the PRO-ACT database, Prize4Life and the NCRI have given companies like ours cause to rethink priorities and strategies regarding ALS, since the abundant clinical and patient data contained within it will help us develop viable Phase II and Phase III treatments for ALS," said Biogen Idec medical director Dr. Doug Kerr.
Pro-ACT contains more than 8,500 fully de-identified unique clinical trial patient records, including demographic, lab, medical history, functional scores, and other data elements. The dataset currently includes both placebo and, in most instances, treatment-arm data from 18 late stage (Phase II/III) ALS clinical trials, resulting in over eight million longitudinally collected data points.
Prize4Life science director Dr. Neta Zach said that the database could help answer research questions, such as which ALS patient subgroups can be expected to live longer, and what were the differences in the disease's progress between men and women.
Published by Globes [online], Israel business news - www.globes-online.com - on December 9, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012
- Tel Aviv market report
- Tel Aviv Stock Exchange
- Israeli stocks in NY
- Arbitrage gaps for dual-listed stocks
- Israeli stocks in Europe
- Israeli stocks on other markets
- Tel Aviv 25 options
- Mutual funds
- Current representative shekel rates
- Historical representative shekel rates
- Bank shekel rates
- Shekel/dollar options